Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ROCHE VERSED WHOLESALER PRICE INCREASED 9.5%

Executive Summary

ROCHE VERSED WHOLESALER PRICE INCREASED 9.5% on July 1 for the most popular dosage, the 5 mg/ml 1 ml vial. A Roche Labs' notice sent to wholesalers July 1 cites higher prices for seven of the eight Versed (midazolam) dosage forms. The increases ranged from 9.5% to 19.5%. The last time Roche Labs raised Versed prices was eight months ago, in October 1990. The highest increase in Versed's average wholesale price was for a box of 10 Versed 5 mg/ml 10 ml multidose vials: $ 671.69 as of July 1. The prices for four other Versed dosages rose 14.9%, with the new prices ranging from $ 143.90 for 2 ml unit dose vials of 5 mg/ml to $ 346.70 for 5 ml multidose vials (both in boxes of 10). Of the 45 drugs included on Roche's price list, only three were not subject to price increases -- Roche's biggest seller, the hospital antibiotic Rocephin (ceftriaxone sodium); and the anti- cancer drugs Roferon-A (interferon alfa-2a); and fluorouracil. Other major Roche drugs with higher prices as of July 1 are Accutane, Bactrim and Bumex, which now cost wholesalers an additional 9.5%. The AWP for the 15 dosage forms of Valium is up 6%, as is the price for the non-barbiturate sedative Dalmane. Valium prices now range from $ 15.78 per 5 mg/ml 10 ml vial to $ 432.25 for 500 10 mg tablets. The top Dalmane price is $ 258.50 for 500 30 mg tablets.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS019470

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel